Sanofi Suffers Second Clinical Setback For Venglustat
Fails In Rare Genetic Kidney Disease Trial
Executive Summary
The French drugmaker has halted a pivotal trial of venglustat in autosomal dominant polycystic kidney disease, a few months after the drug failed as a treatment for Parkinson’s disease. Sanofi will go back to focusing on the therapy's potential in lysosomal storage diseases.
You may also be interested in...
Regulus Hit As Partner Sanofi Pulls Plug On Kidney Drug Study
Sanofi has abandoned its study of lademirsen in Alport disease, but has not given up on the drug just yet as another indication remains in play.
Bayer Advances Parkinson’s Cell And Gene Therapies Into First Human Studies
As Biogen makes history in Alzheimer’s, Bayer is aiming for a breakthrough in Parkinson’s, another major target in neuroscience.
Cost-Cutting Sanofi Resumes Fitusiran Studies, Starts COVID Vaccine Phase IIb This Month
Dupixent was Sanofi’s top-selling product in 2020, but its vaccines division also saw significant growth in the year led by its differentiated influenza vaccines, which helped drive the big pharma’s business during the year, accompanied by significant cost savings.